CRESCENT BIOPHARMA, INC. Cash Flow Statement
CBIO|5 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
CRESCENT BIOPHARMA, INC. used $72M in operating cash flow and negative free cash flow of $72M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Net Income | -$153.9M | -$12.8M | -$11.1M | -$10.6M | $3.7M |
| Depreciation & Amortization | - | $191.5K | $158.7K | $133.1K | $99.9K |
| Operating Cash Flow | -$71.5M | -$8.2M | -$4.3M | -$15.5M | -$10.5M |
| Capital Expenditures | $919.0K | $268.6K | $212.6K | $82.1K | $316.2K |
| Free Cash Flow | -$72.5M | -$8.5M | -$4.5M | -$15.6M | -$10.8M |
| FCF Margin | -668.1% | -42.4% | -29.9% | -391.3% | -70.7% |